Long COVID — the persistent constellation of symptoms that lingers months after acute SARS-CoV-2 infection — affects an estimated 65 million people globally and remains poorly addressed by conventional medicine. The syndrome is multi-system: cognitive impairment (‘brain fog’), profound fatigue, dysautonomia, sleep disruption, exercise intolerance, and persistent psychiatric symptoms. In 2022, the first rigorous double-blind randomized controlled trial of hyperbaric oxygen therapy in this population produced one of the most important findings in the entire Long COVID literature: HBOT drove significant, measurable improvements across cognition, fatigue, sleep, mood, and brain structure.
The Science: Why HBOT Targets the Right Mechanisms
Long COVID is not one disease — it is a constellation of symptoms driven by at least three converging biological problems. Most single-target interventions address one of them, leaving the others intact. HBOT addresses all three simultaneously, which is part of why the early evidence is so striking.
### Microthrombosis and Vascular Damage
Long COVID research has identified persistent microclots — small fibrin deposits that resist normal breakdown — circulating in many patients well after acute infection resolves. These microclots impair tissue perfusion across the brain, lungs, and other organs. HBOT drives several relevant changes:
– Improves microcirculatory flow by elevating dissolved oxygen in plasma
– Promotes endothelial repair through nitric oxide signaling
– Stimulates angiogenesis — new blood vessel formation in tissues with chronic underperfusion
– Reduces vascular inflammation that perpetuates the microclot cycle
### Mitochondrial Dysfunction
A core feature of Long COVID is mitochondrial damage — the cellular energy factories are damaged and producing less ATP, which manifests as profound fatigue and exercise intolerance. HBOT addresses this through:
– Mitochondrial biogenesis — driving the creation of new, healthy mitochondria
– Reduced oxidative damage through balanced antioxidant signaling
– Restored cellular respiration in tissues that have been hypoxic
### Neuroinflammation
The “brain fog,” cognitive impairment, and psychiatric symptoms in Long COVID are increasingly recognized as inflammatory in origin. SARS-CoV-2 appears to trigger persistent low-grade inflammation in the central nervous system. HBOT downregulates inflammatory cytokines, suppresses microglial overactivation, and restores cerebral blood flow to affected regions.
The Landmark Trial: Zilberman-Itskovich 2022
The single most important paper in HBOT for Long COVID is Zilberman-Itskovich et al., Scientific Reports (2022).
### Trial Design
– 73 patients with documented post-COVID condition
– Randomized to either active HBOT (2.0 ATA, 100% oxygen) or sham (1.03 ATA, 21% oxygen)
– Double-blinded — neither patients nor evaluators knew assignment
– 40 sessions over 8 weeks
– Comprehensive evaluation: neurocognitive testing, fatigue assessment, sleep, psychiatric scales, and brain MRI
### Results
The active HBOT group showed significant improvements over sham across:
– Global cognitive function — including attention, executive function, and memory
– Information processing speed
– Fatigue (validated FACIT-F scale)
– Sleep quality
– Psychiatric symptoms — anxiety and depression
– Pain interference
Crucially, brain MRI confirmed structural changes in the active group — meaning the improvements weren’t subjective bias. Specific changes were observed in white matter integrity and cerebral blood flow in regions associated with cognitive processing.
### Why This Trial Matters
Most Long COVID trials are observational or open-label. This was the first rigorous, double-blind, sham-controlled trial to show that an intervention could measurably reverse cognitive and physical symptoms with confirmation on objective imaging. It set a benchmark for the field and remains the most-cited HBOT/Long COVID paper.
The Long COVID Protocol
The clinical protocol for Long COVID derives directly from the Zilberman-Itskovich trial design, with practical adjustments for home use.
### The Standard Protocol
– Pressure: 1.5 ATA for home use; 2.0 ATA replicates the original trial
– Oxygen concentration: 95–100%
– Session length: 60 minutes (some practitioners extend to 90 minutes for severe cases)
– Cadence: 5 sessions per week
– Total sessions: 40 (the dose used in the trial)
### Pacing Considerations
Long COVID patients often have post-exertional malaise (PEM) — disproportionate fatigue or symptom flares after physical or cognitive exertion. The HBOT protocol should respect this:
– Start with 30–45 minute sessions for the first 5–10 sessions, increasing to 60 minutes as tolerated
– Plan for an exhausting first 1–2 weeks; many patients report fatigue worsening before improving
– Build in rest days when needed; better to extend the timeline than provoke a crash
### Expected Trajectory
In the trial cohort, improvements typically followed this pattern:
– Sessions 1–10: Often a mild worsening of fatigue and brain fog before improvement begins
– Sessions 10–20: Sleep often improves first, followed by mood
– Sessions 20–30: Cognitive gains become noticeable — better focus, faster processing, less brain fog
– Sessions 30–40: Compounding gains across cognition, energy, and physical capacity
– Post-protocol: Effects maintained at follow-up; some patients pursue a second course
Where HBOT Fits in a Long COVID Treatment Plan
HBOT is one of the most evidence-backed interventions in Long COVID, but it is rarely a stand-alone solution. The current best-practice consensus among Long COVID-literate clinicians is to combine HBOT with several adjunct therapies:
– Pacing and PEM management — non-negotiable foundation for any Long COVID treatment plan
– Mitochondrial support — CoQ10, NAD+ precursors, B vitamins, alpha-lipoic acid
– Anti-inflammatory diet — addressing the chronic inflammatory state
– Treatment of microclots — anticoagulation under physician guidance in select patients
– Vagal nerve stimulation — both device-based and breathwork approaches
– Sleep optimization — both behavioral and (where appropriate) pharmacological
– Graded movement therapy — careful, PEM-aware reintroduction of physical activity
HBOT’s role is to address the underlying biology — microcirculation, mitochondrial function, neuroinflammation — while these adjuncts manage symptoms and support recovery. Patients running this integrated approach generally outperform those running any single intervention alone.
After 40 sessions of HBOT, Long COVID patients showed significant improvements in cognition, fatigue, sleep, and psychiatric symptoms — with brain MRI confirming structural change.
— Zilberman-Itskovich et al., Scientific Reports (2022)